On September 2, 2021, Chemomab Therapeutics Ltd. announced the appointment of Dr. Dale Pfost as Chief Executive Officer of the Company. The effectiveness of Dr. Pfost’s appointment is subject to the approval of Dr. Pfost’s compensation terms by the shareholders of the Company. Dr. Pfost will replace Dr. Adi Mor, who will step down from her role as Chief Executive Officer, effective as of the appointment of Dr. Pfost, and who will continue to be employed by the Company as Chief Scientific Officer where she will oversee scientific strategy and R&D operations. Dr. Mor will also continue to serve as a Board member.